Quick Facts

• Targeted Conditions: High blood pressure (hypertension).
• Angina Management: Supports the management of chronic stable angina (chest pain) and angina due to coronary artery spasm.
• Therapeutic Goal: To assist in lowering blood pressure and enhancing exercise tolerance.

Altizem-SR is an approved prescription medication utilized for the long-term management of cardiovascular conditions in adults. The primary therapeutic use is to assist in lowering high blood pressure (hypertension). Control of high blood pressure is an essential component of comprehensive cardiovascular risk management and may help reduce the chance of serious events.

The medication is also indicated for the management of different forms of angina pectoris (chest pain). This includes the management of chronic stable angina to support improvement in exercise tolerance and the management of angina resulting from coronary artery spasm. As a treatment option, Altizem-SR may be used alone or in combination with other therapeutic agents to achieve blood pressure goals.

Who Can and Cannot Use Altizem-SR? (Official Regulatory Information)

Official regulatory guidelines strictly define the populations eligible for Altizem-SR (Diltiazem Sustained-Release) primarily based on cardiac health and existing medical conditions.

Contraindicated Populations (Must Not Use)

Altizem-SR is contraindicated and must not be used in patients with the following conditions, unless a functioning ventricular pacemaker is present:

• Sick Sinus Syndrome or Second- / Third-Degree AV Block.
• Severe Hypotension (systolic blood pressure typically under 90 mmHg).
• Acute Myocardial Infarction with Pulmonary Congestion.
• Hypersensitivity to Diltiazem or any formulation components.
• Atrial Fibrillation or Flutter associated with an accessory bypass tract (e.g., Wolff-Parkinson-White syndrome).

Age-Related and Conditional Use

Population	Regulatory Status
Adults	Eligible under standard labeled conditions.
Pediatric Use	Safety and effectiveness have not been established; generally not recommended.
Older Adults	Requires caution; monitoring and often a lower starting dose are advised due to potential decreased organ function.
Hepatic or Renal Impairment	Must be used with caution and close monitoring due to the drug’s metabolism and excretion.

Pregnancy and Lactation Status

Use during pregnancy is generally not recommended or advised only when the potential benefit outweighs the potential risk to the fetus. Diltiazem is excreted into human milk, and a decision is required to either discontinue nursing or discontinue the drug.

Interactions with other medicines and products

Altizem-SR, which contains Diltiazem Hydrochloride, is officially recognized by regulatory authorities as a moderate inhibitor of Cytochrome P450 3A4 (CYP3A4) and a weak inhibitor of P-glycoprotein (P-gp). This pharmacological property governs the majority of documented drug-drug interactions by altering the plasma concentrations of co-administered medications.

Contraindicated Combinations

Certain combinations are formally contraindicated by regulatory bodies due to the high risk of severe adverse outcomes. These prohibited combinations include Dantrolene (intravenous), Ivabradine, Lomitapide, and agents such as Pimozide, Flibanserin, and Lonafarnib.

Clinically Significant Interactions

Co-administration with other medicines may result in two primary types of interaction:

• Increased Exposure of Other Drugs: Diltiazem increases the systemic exposure of medications metabolized by CYP3A4, including certain Statins (e.g., Simvastatin) and Immunosuppressants (e.g., Ciclosporin), and P-gp substrates like Colchicine. For Simvastatin, regulatory labeling specifies a maximum co-administration dose restriction.
• Pharmacodynamic Effects: Additive effects on cardiac function are documented when Diltiazem is combined with other agents that slow heart rate or impair conduction, such as Beta-Blockers and Digoxin.

Drug-Substance Interactions

Consumption of Grapefruit Juice is documented to increase Diltiazem plasma exposure. Co-administration with the herbal product St. John's Wort or the pharmaceutical Rifampin may decrease Diltiazem exposure, reducing its intended effect. Acute Alcohol consumption may alter the sustained-release profile of the medication.

Altizem-SR (Diltiazem) functions as a calcium antagonist, primarily targeting the L-type Voltage-Gated Calcium Channels ( L-VGCCs) found in the heart and blood vessels. By blocking the influx of extracellular calcium ions ( Ca^2+) into the cells, the drug modifies the calcium-dependent excitation-contraction coupling pathway, which is essential for muscle activity and electrical signaling. The mechanism determines the drug’s physiological action by reducing the Ca^2+-dependent steps necessary for electrical and mechanical activity.

The inhibition of Ca^2+ entry into vascular smooth muscle cells causes the arteries to relax, a process called Vasodilation. This mechanism reduces the resistance in the systemic circulation, which decreases the pressure, or afterload, against which the heart must pump blood. This action reduces the mechanical load required of the heart.

Diltiazem’s action on the heart leads to a dual effect: it slows electrical signal conduction through the Atrioventricular (AV) node (Negative Dromotropy) and simultaneously reduces the force of heart muscle contraction (Negative Inotropy). These combined effects of reduced AV node conduction and decreased force of contraction decrease the heart's overall workload and oxygen demand of the myocardial tissue.

How to Use Altizem-SR

Altizem-SR is a prescription-only medication administered via the oral route in a sustained-release (SR) tablet or capsule form. This formulation is designed to release Diltiazem Hydrochloride gradually, necessitating that the tablet or capsule be swallowed whole. It must not be crushed, split, or chewed, as doing so compromises the controlled-release mechanism.

The medication is administered once daily at a consistent time each day. The labeled starting dose for adults is typically in the range of 180 mg to 240 mg once per day. Titration to a higher dose, up to a maximum of 540 mg once daily depending on the specific extended-release form, must be performed gradually. Dosage adjustments are directed to occur at intervals of 7 to 14 days to allow for the full effect of chronic therapy to be observed.

Administration Context and Special Populations

Altizem-SR may be administered without regard to food. If a dose is missed, instructions advise taking the next scheduled dose at the usual time, without taking two doses to make up for the missed one.

For specific populations, guidelines advise caution. Due to potential changes in how the medicine is processed, the initiation of therapy for older adults or those with hepatic or renal impairment may require starting at a lower dose than the standard adult initial dose.

Recent Clinical Evidence

---

Overview of Studies

Research has explored whether the combination affects clinical outcomes in adults with chronic, non-cancer pain. Studies have evaluated the use of the combination, and research has investigated the hypothesis that the combination affects both inflammatory and nerve-signaling pathways. Observed results included a reduction of daily pain scores over the study period.

Research findings from studies lasting up to 12 weeks included reports of improvements in quality of life. Evaluations showed a reduction in pain scores from baseline, with an average reduction of 30% reported across study groups.

---

Safety and Tolerability Profile

Tolerability was assessed, with results indicating the combination was generally tolerated by participants in the evaluated studies. Common reported side effects included mild drowsiness and temporary gastric discomfort. In the evaluated studies, researchers noted these were often reported to have resolved within the first week of use.

Studies noted that individuals with kidney impairment were excluded from or had specific monitoring in the trials. The most serious reported events were linked to pre-existing cardiovascular conditions, though the incidence was low.

---

Long-Term Research

A study examining long-term use (up to 1 year) evaluated whether the combination maintained an effect compared to monotherapy. Researchers reported that the incidence of adverse events did not substantially increase over the longer follow-up period. It is not yet clear whether the long-term benefits outweigh the risks of prolonged use, and further research is ongoing to establish a definitive profile.

Key Studies & References

1. Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies
2. Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety
3. Comparison of tanezumab and non-steroidal anti-inflammatory drugs in efficacy and safety for chronic low back pain: a systematic review and meta-analysis of randomized controlled trials

Common questions about Altizem-SR (FAQ)

Q: How long after starting Altizem-SR should a person expect to feel the full effects?

A: According to official product information, the maximum effect of Altizem-SR in lowering blood pressure is typically observed after about 14 days of consistent, regular use. Patient response and the time to observe the full effects can vary.

Q: Is there published research evidence showing Altizem-SR improves exercise tolerance for angina?

A: Research cited in regulatory documents indicates that Altizem-SR (diltiazem) can significantly increase the duration of exercise before the onset of chest pain (angina). This evidence is contained within official documents regarding its use in the management of chronic stable angina.

Q: Are there special considerations for elderly patients taking Altizem-SR?

A: Official guidelines advise caution when starting therapy for older adults. Official guidelines often note that the initiation of therapy may involve a lower starting dose than the standard adult dose, as the rate at which the drug is processed by the body can be slower.

Q: Is Altizem-SR a type of beta-blocker medicine?

A: No, Altizem-SR is classified as a calcium channel blocker (or calcium antagonist). It belongs to the Benzothiazepine class of medicines and is not classified as a beta-blocker.

Q: What are the typical uses of Altizem-SR besides treating high blood pressure?

A: In addition to high blood pressure, Altizem-SR is officially indicated for the management of chronic stable angina (chest pain that occurs with activity) and angina due to coronary artery spasm (a type of chest pain that can happen at rest).

Q: Can Altizem-SR be used to help manage heart rhythm issues like atrial fibrillation?

A: Authoritative sources note that diltiazem is sometimes used by healthcare providers to help control the heart rate in patients with certain types of abnormal heart rhythms, such as atrial fibrillation or atrial flutter.

Q: How is Altizem-SR compare broadly to other non-dihydropyridine calcium channel blockers?

A: Altizem-SR (Diltiazem) is classified as a Benzothiazepine. This drug subclass is noted by authoritative sources to have a direct effect on heart rate and conduction, which provides a high-level difference from other non-dihydropyridines like Verapamil.

Q: Does Altizem-SR start working immediately, or does it take a while to build up in the system?

A: As a sustained-release medicine, Altizem-SR is designed to release gradually. While the effect is immediate in action, full patient benefit, such as maximum blood pressure control, may take one to two weeks of regular daily treatment to achieve.

Q: Is it normal to get swollen ankles or feet when first starting Altizem-SR?

A: Peripheral edema, or swelling of the ankles and feet, is listed in regulatory documents as a very common side effect reported in clinical data. This is often an expected effect of the medicine.

Q: Why does Altizem-SR cause dizziness or lightheadedness in some patients?

A: Dizziness and lightheadedness are common side effects that can occur, especially when moving from a sitting or lying position to standing. This occurrence may be related to the medicine’s function of lowering blood pressure.

Q: Are headaches a common side effect of Altizem-SR?

A: Yes, official product information lists headache as one of the most frequently reported side effects observed during clinical trials of diltiazem.

Q: Does Altizem-SR frequently cause constipation?

A: Constipation is listed as a common gastrointestinal side effect. This is a known effect of calcium channel blockers, which can affect the smooth muscle function in the digestive system.

Q: What common stomach-related side effects might a person experience with Altizem-SR?

A: Common gastrointestinal side effects observed in official clinical data include constipation, indigestion or upset stomach (dyspepsia), and some reports of stomach pain.

Q: Can taking Altizem-SR make a person feel more tired or fatigued?

A: Official documents list unusual tiredness or weakness as a possible side effect of the medication. If persistent, this effect is recommended to be noted during medical consultations.

Q: What are the signs of a potentially serious side effect, such as a liver problem, to watch for?

A: Symptoms that may indicate a serious liver problem include yellowing of the skin or eyes (jaundice), unusually dark urine, loss of appetite, or persistent pain in the upper right part of the stomach. These effects are described as serious and require medical evaluation if they occur.

Q: Does Altizem-SR have the potential to slow down the heart rate too much?

A: Yes, Altizem-SR can affect the heart's electrical system. A slow or irregular heartbeat (bradycardia) is listed in regulatory documents as a potential side effect due to its action on the AV node.

Q: Is there a risk of low blood pressure (hypotension) while using Altizem-SR?

A: Since the medicine is intended to lower blood pressure, there is a risk of it dropping too low. Hypotension (low blood pressure) is a possible side effect, and the drug is contraindicated in patients with severe hypotension.

Q: Can Altizem-SR cause severe skin reactions, like a widespread rash or peeling?

A: Severe skin reactions are rare but possible with diltiazem. These serious reactions can involve blistering, peeling, or loosening of the skin and are described in regulatory documents as needing urgent medical evaluation.

Q: What are the possible symptoms of heart failure that Altizem-SR users should be aware of?

A: Regulatory sources list new or worsening signs of heart failure as serious effects to watch for. Symptoms can include unexplained shortness of breath, marked swelling of the ankles or feet, or rapid, unusual weight gain.

Q: Is it acceptable to drink alcohol in moderation while taking Altizem-SR?

A: Official information advises that consuming alcohol can increase the dizziness that is commonly caused by Altizem-SR. This potential interaction is noted for individuals consuming alcoholic beverages.

Q: Can eating grapefruit or drinking grapefruit juice interfere with Altizem-SR?

A: Authoritative sources note that grapefruit juice can interfere with the body's metabolism of diltiazem. This is because grapefruit juice is known to inhibit a specific enzyme that breaks down the medicine.

Q: Does Altizem-SR interact with common cholesterol-lowering medicines like statins?

A: Regulatory information indicates that Altizem-SR can slow down the removal of certain statin medicines from the body. This may necessitate monitoring or adjustment of the statin, as outlined in official guidelines.

Q: Are there any specific over-the-counter (OTC) medicines or herbal supplements to avoid?

A: Authoritative medical sources note that the herbal product St. John’s wort can interact with diltiazem. It is essential that a healthcare provider is informed about all OTC medicines and supplements being taken.

Q: What types of heart conditions or low heart rates would prevent a person from using Altizem-SR?

A: Official contraindications for Altizem-SR include certain severe heart conduction issues, such as sick sinus syndrome and second- or third-degree AV block. Official documents describe an exception if a functioning ventricular pacemaker is present.

Q: Can a person with pre-existing kidney or liver problems use Altizem-SR?

A: Official guidelines advise caution when Altizem-SR is used in patients with kidney or liver disease. Since the drug is processed by these organs, impaired function may slow down the medicine’s removal, potentially increasing its effects.

Q: What are the considerations for women who are pregnant, planning pregnancy, or breastfeeding?

A: Official warnings state that the use of Altizem-SR during pregnancy is generally not recommended unless the potential benefit justifies the risk. The drug is generally not recommended while breastfeeding.

Q: Can Altizem-SR be used by patients who have previously had a heart attack?

A: The medicine is contraindicated (should not be used) in patients who have experienced a recent heart attack (acute myocardial infarction) accompanied by a condition called pulmonary congestion.

Q: Is it true that patients should not suddenly stop taking Altizem-SR?

A: Regulatory advice states that patients should not stop taking Altizem-SR abruptly. Discontinuation, if necessary, is recommended to occur under the supervision of a healthcare provider.

Q: What is the general duration of treatment for conditions like high blood pressure or angina?

A: For chronic conditions such as high blood pressure and stable angina, regulatory-aligned information notes that treatment with Altizem-SR may need to be taken regularly for the long term.

Q: Can Altizem-SR cause a patient to feel dizzy when standing up too quickly?

A: Official drug information indicates that a person may feel dizzy, lightheaded, or even faint upon standing up too quickly. This is due to the medicine's effect on blood pressure regulation and is described in the product information.

Q: Are there any known non-serious side effects that usually go away after a few weeks?

A: Regulatory-aligned consumer information suggests that many common side effects are mild and may gradually lessen as the body adjusts to the medication over time. If a side effect is persistent or bothersome, patients are generally advised to discuss it with a healthcare provider.

Q: Can Altizem-SR interact with medicines used during surgery or dental procedures?

A: Official product information advises that the healthcare team (doctor or dentist) should be informed of diltiazem use before any type of surgery or dental procedure.

Q: Does Altizem-SR have any known effects on weight (gain or loss)?

A: Weight increase is listed as a potential metabolic side effect of diltiazem in clinical trial data. Unexplained or rapid changes in weight are generally recommended to be monitored by a healthcare provider.

Q: What information is available regarding the use of Altizem-SR in pediatric populations?

A: Official dosing guidelines state that the use and dose in children must be determined by a healthcare provider.

Q: Does Altizem-SR have a different effect on the heart rate compared to other blood pressure medicines?

A: Yes, unlike some other blood pressure medicines, Altizem-SR (a non-dihydropyridine) is noted by authoritative sources to have a direct effect on the heart. It can slow electrical signals within the heart and reduce the force of the heart muscle contraction.

Storage and Disposal Conditions for Altizem-SR

Altizem-SR (Diltiazem Hydrochloride Extended-Release) must be stored under specific environmental and container rules to maintain its stability.

---

Storage Requirements

Temperature and Environment: The product must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medication must be protected from excessive moisture.

Container and Safety: It must be kept in a tightly closed or well-closed container as dispensed. For safety, Altizem-SR must be kept out of the reach of children.

---

Disposal Instructions

Unused or expired Altizem-SR must be disposed of according to local regulations or via a certified medication take-back program. Disposal should follow the directions provided by a healthcare professional or pharmacist.